$JAN

Janus Living, Inc. (JAN): Results of Operations and Financial Condition

Janus Living, Inc. (JAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.3 4 ex99306302026.htm EX-99.3 Document Exhibit 99.3 Discussion and Reconciliation of Janus Living's Non-GAAP Financial Measures June 30, 2026 (Unaudited) Definitions Adjusted Fixed Charge Coverage Fixed Charge Coverage Adjusted EBITDAre divided by Fixed Charges. Adjusted Fi

Original reporting
Published Aug 4, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$JAN
Neutral
low confidence
Mentioned
$JAN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JANNeutralLow
01

Why it matters

Based on the provided excerpt, the filing mainly explains how Janus Living calculates supplemental metrics (EBITDAre, Adjusted EBITDAre, and fixed-charge coverage) rather than disclosing new performance numbers.

02

Market read

No new earnings, guidance, covenant breach, or transaction details are present in the excerpt, so trading impact is likely minimal.

03

What to watch

If the full Exhibit 99.3 includes actual June 30, 2026 results and reconciliations, that could raise relevance; the provided text is only definitions.

Relevance 7/10Novelty 1/10Timing: Filed Aug 4, 2026, after-hours (8-K submission window).

Background

The SEC 8-K references Item 2.02 and includes Exhibit 99.3 describing non-GAAP financial measures for the period ended June 30, 2026.

Company-level read

Ticker impact

$JANNeutralLow confidence
Context

Janus Living filed an 8-K with Item 2.02, attaching Exhibit 99.3 that defines non-GAAP metrics like Adjusted EBITDAre and fixed-charge coverage.

Expected impact

Low likelihood of a directional move based on the provided text alone.

Evidence & confidence

The excerpt contains definitions and reconciliation methodology for non-GAAP measures, but no new financial results, covenant ratios, or forward-looking guidance values.

Market effects

Limited, since the excerpt does not include sector-wide regulatory or operating changes.

None indicated in the provided text.

None indicated in the provided text.

Counterpoint

Traders may still use the attached exhibit to interpret upcoming covenant or liquidity discussions, but the excerpt does not show those figures.

Key entities

  • Janus Living, Inc.

    Subject of the 8-K filing, with Exhibit 99.3 defining non-GAAP measures used in its financial reporting.

Related articles

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JANMed

JAN (JAN) – Research Analysts’ Weekly Ratings Changes

Analysts at several firms adjusted ratings and price targets for JAN (NYSE: JAN) in May 2026, with Scotiabank raising its target to $30 (from $28) and Barclays lifting to $30 (from $26), among others. In April, multiple firms initiated coverage with targets from $26 to $29. JAN also declared a quarterly dividend of $0.1599 per share, payable June 24 to holders of record June 12.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

$BRK-BMed

Berkshire Hathaway Just Did Something It Hasn’t Done in More Than 3 Years

Berkshire Hathaway reported Q2 2026 cash and Treasury bills of $365.5 billion, down from $397.4 billion in Q1, ending a 14-quarter streak as a net seller. According to Berkshire, CEO Greg Abel became a net buyer of equities, adding about $20 billion net, and increased buybacks to $4.5 billion. Apple fell to 20% of the portfolio; Alphabet rose after a $10 billion investment.

$LIONMed

Lionsgate Studios Q1 Earnings Call Highlights

Lionsgate (NYSE:LION) Q1 earnings call said it expects downstream revenue from films through fiscal 2027 and that The Hunger Games: Sunrise on the Reaping could support later-year results. Television revenue was $189 million, segment profit $10 million. Trailing 12-month library revenue was $987 million, backlog $1.5 billion. Net debt fell $121 million to about $1.5 billion; leverage improved to 4.3x.